Celiac disease (CD) is a major public health concern because it affects 1% of the population in certain regions and it is often underestimated. The disease is frequently associated with other autoimmune diseases and can take up to several years before it is properly diagnosed.
The classic diagnostic tools (tTg, EMA, gliadins) have known limitations and there are several studies reporting that even with human recombinant tTg assays, there are still cases of sero-negative celiac disease patients which may go unnoticed in a laboratory diagnosis, based on tTg antibodies alone.
AESKU.DIAGNOSTICS has placed huge efforts on the research, development, production and optimization of new markers for CD, to help the laboratories shortening the time to diagnosis which has an important impact on the health improvement status of the patients.
In 2001, AESKU.DIAGNOSTICS presented a new important antigen strategy for celiac detection: the AESKU.DIAGNOSTICS Celiac neo-epitopes used in our AESKULISA® tTg New Generation kits.
The new epitopes are produced under controlled conditions by the modification and crosslink reaction of specially developed gliadin peptides with tissue transglutaminase leading to an antigen which is extrinsic to the immune system and is currently in discussion to be one of the causes for the autoimmune reaction in celiac disease.